The FDA today released draft guidance for industry on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins. The guidance document provides recommendations as to whether—and when—comparative clinical immunogenicity studies will be needed to support an application to the FDA for insulin products under the biosimilar approval pathway.
The FDA today released draft guidance for industry on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins. The guidance document provides recommendations as to whether—and when—comparative clinical immunogenicity studies will be needed to support an application to the FDA for insulin products under the biosimilar approval pathway.
As of March 2020, insulins will be regulated as biologics, and as such, developers will be able to seek licensure for subsequent-entry insulins under the biosimilar approval pathway after that time, whereas they are currently treated as follow-ons.
In the past, the FDA has generally advised that clinical studies should be provided to evaluate potential risks from immunogenicity with insulin products. The FDA has also taken the stance that data from a comparative clinical immunogenicity study may be needed to evaluate risk and clinical impact of a proposed biosimilar or interchangeable insulin.
In the current guidance, the FDA reports that, in its current thinking, if a comparative analytical assessment demonstrates that products are highly similar, “there would be little or no residual uncertainty regarding immunogenicity.”
In such cases, explains the guidance, a proposed biosimilar or interchangeable insulin would be expected to have “minimal or no risk” of clinical impact from immunogenicity, and a comparative immunogenicity study would likely be unnecessary. Studies would still be needed in cases in which there is uncertainty raised by such factors as differences in certain impurities or novel excipients, however.
The updated recommendation is based on a multidisciplinary evaluation that considered the relatively small structure of insulin compared with other biologics, extensive experience with immunogenicity in insulins, experience with insulin products, public comments to the FDA, updated recommendations from the European Medicines Agency, and the published scientific literature.
The FDA expects Biologics License Applications for biosimilar and interchangeable insulins to include adequate chemistry, manufacturing, and control information; a comprehensive comparative analytical assessment; a comparative clinical pharmacology study; and an immunogenicity assessment that shows why a comparative clinical study is not needed.
Interchangeable insulins will not generally need switching studies, says the guidance, as long as statutory criteria for licensure are otherwise met.
The FDA will receive comments on the guidance for the next 60 days on the Federal Register.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.